Pfizer's Xeljanz Is First JAK Positive In PsA But Challenges Ahead
Executive Summary
Pfizer’s oral JAK inhibitor Xeljanz is set to lead the JAK inhibitors to market in psoriatic arthritis following positive Phase III data particularly in joint inflammation, but skin findings were disappointing.
You may also be interested in...
Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?
Pfizer's JAK inhibitor met its co-primary efficacy endpoints, but US FDA still wants discussion of lack of impact on radiographic progression.
Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
The latest drug development news and highlights from our US FDA Performance Tracker.
Pipeline-In-A-Pill: Still A Winning Strategy?
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.